AlphaMedixTM在治疗先进的神经内分泌肿瘤方面显示出强有力的成果,在第二阶段试验中改善了存活率和可管理的副作用。 AlphaMedix™ showed strong results in treating advanced neuroendocrine tumors, with improved survival and manageable side effects in a phase 2 trial.

AlphaMedixTM(212Pb-DOTAMTATE)是一种实验性定向甲型疗法,在对先进的胃肠血清炎神经内分泌肿瘤的第二阶段试验中实现了所有主要目标,显示了有意义的反应率,改善了接受治疗的神经病人和以前接受治疗的病人的存活率,安全情况可以控制。 AlphaMedix™ (212Pb-DOTAMTATE), an experimental targeted alpha therapy, met all primary goals in a phase 2 trial for advanced gastroenteropancreatic neuroendocrine tumors, showing meaningful response rates and improved survival in both treatment-naïve and previously treated patients, with a manageable safety profile. 该疗法针对癌症细胞使用短程阿尔法辐射,于2024年2月获得FDA突破疗法指认。 The therapy, which uses short-range alpha radiation to target cancer cells, earned FDA Breakthrough Therapy Designation in February 2024. 成果将提交给2025年欧洲无害环境管理组织大会,并可能指导今后的监管步骤。 Results will be presented at the 2025 ESMO Congress and may guide future regulatory steps. 该治疗尚未获得批准。 The treatment is not yet approved.